<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00802919</url>
  </required_header>
  <id_info>
    <org_study_id>081/C02</org_study_id>
    <secondary_id>FDA IND 102,411</secondary_id>
    <nct_id>NCT00802919</nct_id>
  </id_info>
  <brief_title>Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors</brief_title>
  <official_title>Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors, Independent Investigator Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nathan Kline Institute for Psychiatric Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nathan Kline Institute for Psychiatric Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 8-week double-blind placebo controlled parallel group study of the efficacy of
      varenicline (Chantix) for smoking cessation in schizophrenic patients, and its effect on
      cognitive function in patients with schizophrenia.At some sits evaluation of smoking measures
      is extended to 12 weeks. Correlations will be made with biological predictors of efficacy: a)
      measures of nicotinic receptors in lymphocytes b) DNMT1 and GAD67 mRNA in lymphocytes.
      Subjects will be current cigarette smokers or history of regular smokers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a double-blind placebo controlled study of varenicline and matched placebo in
      patients with a diagnosis of schizophrenia or schizoaffective psychosis who were treated with
      antipsychotic medication and were cigarette smokers. Three sites (2 U.S., 1 Israel) were
      supported by the Stanley grant. A similar independently supported study was conducted in
      Beijing, China. We were allowed to access these data and combine them for our analysis of
      results. Subjects at each site participated in a protocol which was approved by their
      institutional IRB. All subjects signed informed consent.

      The study evaluated multiple measures of cigarette smoking, cognitive functions by MATRICS
      battery (Measurement and Treatment Research to Improve Cognition in Schizophrenia), and
      psychiatric symptoms by PANSS (Positive and Negative Symptom Scale), SANS (Schedule For
      Assessment Of Negative Symptoms), and Calgary Depression scales. Lymphocytes were collected
      for measurement of epigenetically related mRNA's.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cotinine Level</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks</time_frame>
    <description>plasma cotinine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Cognitive Performance</measure>
    <time_frame>basline and 8 weeks (or end of study iif patient ended participation before the 8-weeks)</time_frame>
    <description>The MATRICS Consensus Cognitive Battery (MCCB)(Measurement and Treatment Research to Improve Cognition in Schizophrenia) was used to measure cognitive performance. Six Domain scores and a Composite score are calculated by the proprietary MCCB Computer Scoring Program (modified beta version) from raw scores on 10 individually administered subtests. The social cognition test was not assessed in this study. The Domain T-scores are percentile-ranked and range from &lt;20 (&lt;0.1 percentile) to &gt;80 (&gt;99.9 percentile). The Composite scores are also percentile-ranked and range from &lt;213 (T&lt;20, &lt;0.1 percentile) to &gt;487 (T&gt;80, &gt;99.9 percentile). Higher scores after baseline represent better outcomes. Here we report difference scores from post-treatment and baseline with positive difference scores representing better outcomes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Psychiatric Symptoms</measure>
    <time_frame>baseline, 4 weeks, 8 weeks</time_frame>
    <description>The Positive and Negative Syndrome Scale (PANSS) was used to measure psychiatric symptoms. Item scores ranged from 1 (Absent) to 6 (Severe) for symptoms on the Positive Scale (total subscale range: 7-42), the Negative Scale (total subscale range: 7-42), and the General Psychopathology Scale (total subscale range:16-96). All three subscales were summed for the PANSS total score (total scale range: 30-180). Scores closer to 30 after baseline represented better outcomes. Here we report difference scores from post-treatment and baseline with negative difference scores representing better outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Basellne in Calgary Depression Scale Score</measure>
    <time_frame>baseline, 4 weeks, 8 weeks</time_frame>
    <description>The Calgary Depression Scale for Schizophrenia. The scale has 9 items with ratings of 0 to 3 on each item. Total score can vary from 0 to 27. Higher scores indicate more depression. Negative change scores indicate decreasing depression.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Cigarette Smoking</condition>
  <arm_group>
    <arm_group_label>Varenicline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Varenciline 1-2 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matched Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo for varenicline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varenicline</intervention_name>
    <description>Varenicline 1-2 mg/day</description>
    <arm_group_label>Varenicline</arm_group_label>
    <other_name>Chantix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for varenicline</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Matched Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Diagnosis of Schizophrenia or Schizoaffective Disorder Current Cigarette Smoker or History
        of Chronic Cigarette smoking Age 18-65 Currently taking antipsychotic medication

        Exclusion Criteria:

        prior history of hospitalization for acute myocardial infarction or stroke, or persistent
        angina pectoris with current symptoms Patients who have previously tried varenicline and
        have stopped taking it because of side-effects of severe nausea or vomiting suicide attempt
        in the last year and or have had prominent or serious suicidal thoughts in the past year
        Women who are pregnant, nursing, or unable to use reliable contraception significant renal
        impairment(Creatinine â‰¥ 1.5) baseline Hamilton Depression Scores is &gt;20
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert C. Smith, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nathan Kline Institute for Psychiatric Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Manhattan Psychatirc Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nathan Kline Insitute for Psychiatric Research</name>
      <address>
        <city>Orangeburg</city>
        <state>New York</state>
        <zip>10962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University Institute of Mental Health</name>
      <address>
        <city>Beijing</city>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Division of Psychiatry, Chaim Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Smith R, Amiaz, R,, Tian-Mei S, Maayan L, Jin H, Boules S, et al. (2013): Varenicline effects on smoking, cognition, and psychiatric symptoms in schizophrenia. Neuropsychopharmacology. 38:s273-s434.</citation>
  </reference>
  <results_reference>
    <citation>Smith RC, Amiaz R, Si TM, Maayan L, Jin H, Boules S, Sershen H, Li C, Ren J, Liu Y, Youseff M, Lajtha A, Guidotti A, Weiser M, Davis JM. Varenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia: A Double-Blind Randomized Trial. PLoS One. 2016 Jan 5;11(1):e0143490. doi: 10.1371/journal.pone.0143490. eCollection 2016.</citation>
    <PMID>26730716</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2008</study_first_submitted>
  <study_first_submitted_qc>December 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2008</study_first_posted>
  <results_first_submitted>December 15, 2016</results_first_submitted>
  <results_first_submitted_qc>October 24, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 2, 2017</results_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nathan Kline Institute for Psychiatric Research</investigator_affiliation>
    <investigator_full_name>Robert C. Smith MD PhD</investigator_full_name>
    <investigator_title>Research Psychiatrist, Principal Investigagtor</investigator_title>
  </responsible_party>
  <keyword>schizophrenia</keyword>
  <keyword>smoking</keyword>
  <keyword>nicotine</keyword>
  <keyword>cognitive deficits</keyword>
  <keyword>nicotinic receptors</keyword>
  <keyword>Cognitive Deficits in Schizophrenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Cognition Disorders</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Overall, 93 subjects were consented, 2 withdrew consent before randomization, and 87 provided evaluable data on at least one outcome measure. The number enrolled 93, is less than the number started 91, because 2 patients withdrew consent before randomization</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Varenicline</title>
          <description>Varenicline 1-2 mg/day
Varenicline: Varenicline 1-2 mg/day</description>
        </group>
        <group group_id="P2">
          <title>Matched Placebo</title>
          <description>placebo for varenicline
Placebo for varenicline: Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Varenicline</title>
          <description>Varenicline 1-2 mg/day
Varenicline: Varenicline 1-2 mg/day</description>
        </group>
        <group group_id="B2">
          <title>Matched Placebo</title>
          <description>placebo for varenicline
Placebo for varenicline: Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="45"/>
            <count group_id="B3" value="87"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.6" spread="8.9"/>
                    <measurement group_id="B2" value="43.6" spread="10.6"/>
                    <measurement group_id="B3" value="44.7" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>white</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>black-AA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chinese han</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cotinine Level</title>
        <description>plasma cotinine</description>
        <time_frame>Baseline, 4 weeks, 8 weeks</time_frame>
        <population>Data were available for cotinine analysis in mixed model analysis of co covariance on 34 participants in the varenicline arms and 36 participants in the placebo arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline</title>
            <description>Varenicline 1-2 mg/day
Varenicline: Varenicline 1-2 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Matched Placebo</title>
            <description>placebo for varenicline
Placebo for varenicline: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Cotinine Level</title>
          <description>plasma cotinine</description>
          <population>Data were available for cotinine analysis in mixed model analysis of co covariance on 34 participants in the varenicline arms and 36 participants in the placebo arm.</population>
          <units>cotinine ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="257.9" spread="15.9"/>
                    <measurement group_id="O2" value="258.6" spread="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176.0" spread="16.0"/>
                    <measurement group_id="O2" value="252.1" spread="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147.0" spread="17.9"/>
                    <measurement group_id="O2" value="264.6" spread="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Cognitive Performance</title>
        <description>The MATRICS Consensus Cognitive Battery (MCCB)(Measurement and Treatment Research to Improve Cognition in Schizophrenia) was used to measure cognitive performance. Six Domain scores and a Composite score are calculated by the proprietary MCCB Computer Scoring Program (modified beta version) from raw scores on 10 individually administered subtests. The social cognition test was not assessed in this study. The Domain T-scores are percentile-ranked and range from &lt;20 (&lt;0.1 percentile) to &gt;80 (&gt;99.9 percentile). The Composite scores are also percentile-ranked and range from &lt;213 (T&lt;20, &lt;0.1 percentile) to &gt;487 (T&gt;80, &gt;99.9 percentile). Higher scores after baseline represent better outcomes. Here we report difference scores from post-treatment and baseline with positive difference scores representing better outcomes.</description>
        <time_frame>basline and 8 weeks (or end of study iif patient ended participation before the 8-weeks)</time_frame>
        <population>N's varied from 25-32 in varenicline group and 29-35 in placebo group because all subjects did not complete all parts of MATRICS battery.Maximum number of participants is entered for number of participants because this cell entry does not allow entry of variable number of participations ( e.g. 25-32). for different scores..</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline</title>
            <description>Varenciline 1-2 mg/day
Varenicline: Varenicline 1-2 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Matched Placebo</title>
            <description>placebo for varenicline
Placebo for varenicline: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cognitive Performance</title>
          <description>The MATRICS Consensus Cognitive Battery (MCCB)(Measurement and Treatment Research to Improve Cognition in Schizophrenia) was used to measure cognitive performance. Six Domain scores and a Composite score are calculated by the proprietary MCCB Computer Scoring Program (modified beta version) from raw scores on 10 individually administered subtests. The social cognition test was not assessed in this study. The Domain T-scores are percentile-ranked and range from &lt;20 (&lt;0.1 percentile) to &gt;80 (&gt;99.9 percentile). The Composite scores are also percentile-ranked and range from &lt;213 (T&lt;20, &lt;0.1 percentile) to &gt;487 (T&gt;80, &gt;99.9 percentile). Higher scores after baseline represent better outcomes. Here we report difference scores from post-treatment and baseline with positive difference scores representing better outcomes.</description>
          <population>N's varied from 25-32 in varenicline group and 29-35 in placebo group because all subjects did not complete all parts of MATRICS battery.Maximum number of participants is entered for number of participants because this cell entry does not allow entry of variable number of participations ( e.g. 25-32). for different scores..</population>
          <units>T scores from MATRICS battery</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MATRICS composite score diff from baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19" spread="2.14"/>
                    <measurement group_id="O2" value="1.97" spread="1.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MATRICS Speed of Processing diff from baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.03" spread="1.52"/>
                    <measurement group_id="O2" value="4.08" spread="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MATRICS attention-vigilance diff from baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.49" spread="1.99"/>
                    <measurement group_id="O2" value="4.33" spread="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MATRICS working memory diff from baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" spread="1.82"/>
                    <measurement group_id="O2" value="5.29" spread="1.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MATRICS verbal learning diff from baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94" spread="1.00"/>
                    <measurement group_id="O2" value="0.01" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MATRICS visual learning diff from baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.75" spread="2.26"/>
                    <measurement group_id="O2" value="7.85" spread="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MATRICS reasoning-rob sol diff from baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" spread="0.78"/>
                    <measurement group_id="O2" value="2.79" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Psychiatric Symptoms</title>
        <description>The Positive and Negative Syndrome Scale (PANSS) was used to measure psychiatric symptoms. Item scores ranged from 1 (Absent) to 6 (Severe) for symptoms on the Positive Scale (total subscale range: 7-42), the Negative Scale (total subscale range: 7-42), and the General Psychopathology Scale (total subscale range:16-96). All three subscales were summed for the PANSS total score (total scale range: 30-180). Scores closer to 30 after baseline represented better outcomes. Here we report difference scores from post-treatment and baseline with negative difference scores representing better outcomes.</description>
        <time_frame>baseline, 4 weeks, 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Varenicline</title>
            <description>Varenicline 1-2 mg/day
Varenicline: Varenicline 1-2 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Matched Placebo</title>
            <description>placebo for varenicline
Placebo for varenicline: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Psychiatric Symptoms</title>
          <description>The Positive and Negative Syndrome Scale (PANSS) was used to measure psychiatric symptoms. Item scores ranged from 1 (Absent) to 6 (Severe) for symptoms on the Positive Scale (total subscale range: 7-42), the Negative Scale (total subscale range: 7-42), and the General Psychopathology Scale (total subscale range:16-96). All three subscales were summed for the PANSS total score (total scale range: 30-180). Scores closer to 30 after baseline represented better outcomes. Here we report difference scores from post-treatment and baseline with negative difference scores representing better outcomes.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PANSS Total wk4 -baseline diff</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.56" spread="1.29"/>
                    <measurement group_id="O2" value="-0.86" spread="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PANSS Total wk8-baseline diff</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.05" spread="1.35"/>
                    <measurement group_id="O2" value="-0.97" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PANSS Depression Factor wk4-basline diff</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.67" spread="0.24"/>
                    <measurement group_id="O2" value="0.23" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PANSS depressor factor wk8-baseline diff</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.67" spread="0.25"/>
                    <measurement group_id="O2" value="-0.10" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Basellne in Calgary Depression Scale Score</title>
        <description>The Calgary Depression Scale for Schizophrenia. The scale has 9 items with ratings of 0 to 3 on each item. Total score can vary from 0 to 27. Higher scores indicate more depression. Negative change scores indicate decreasing depression.</description>
        <time_frame>baseline, 4 weeks, 8 weeks</time_frame>
        <population>Not all patients had relevant responses on Calgary Depression Scale. Data are analyzed for 36 subjects randomized to varenicline and 38 subjects randomized to placebo (total N=74).</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline</title>
            <description>Varenicline 1-2 mg/day
Varenicline: Varenicline 1-2 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Matched Placebo</title>
            <description>placebo for varenicline
Placebo for varenicline: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Basellne in Calgary Depression Scale Score</title>
          <description>The Calgary Depression Scale for Schizophrenia. The scale has 9 items with ratings of 0 to 3 on each item. Total score can vary from 0 to 27. Higher scores indicate more depression. Negative change scores indicate decreasing depression.</description>
          <population>Not all patients had relevant responses on Calgary Depression Scale. Data are analyzed for 36 subjects randomized to varenicline and 38 subjects randomized to placebo (total N=74).</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Calgrapy Dep totl wk4-baseline diff</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.63" spread="0.24"/>
                    <measurement group_id="O2" value="-0.72" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>calgrapy dep wk8-baseline diff</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.79" spread="0.26"/>
                    <measurement group_id="O2" value="-0.88" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Varenicline</title>
          <description>Varenicline 1-2 mg/day
Varenicline: Varenicline 1-2 mg/day</description>
        </group>
        <group group_id="E2">
          <title>Matched Placebo</title>
          <description>placebo for varenicline
Placebo for varenicline: Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>psychiatric decompensation not study drug related</sub_title>
                <description>after discharge from hospital patient decoenssated because of drug abuse and noncompliance with medication</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>auditory hallucination not study drug related</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>patient developed auditory hallucinations although symptom scores had decreased on varenicline</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>verbal agression</sub_title>
                <description>verbal aggression lead to [psychiatric hospitalization. Patient on placebo study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert C. Smith MD</name_or_title>
      <organization>Nathan Kline Institute for Psychiatric Research</organization>
      <phone>845-398-6531</phone>
      <email>rsmith@nki.rfmh.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

